Evaluation of the efficacy of oral nanocurcumin formulation in
preventing cisplatin-induced nephrotoxicity in cancer patients: A
triple-blind placebo-controlled clinical trial
Abstract
Chemotherapy induced nephrotoxicity is one of the most common
complications in cancer patients, especially under treatment with
cisplatin containing regimens, which may require cisplatin dose
reduction and in some cases discontinuation of the treatment, which
interferes with treatment process. Curcumin is an antioxidant and
anti-inflammatory compound and the most important active component of
curcuma longa. In this study, the preventive effect of nano-curcumin
oral formulation on cisplatin-induced nephrotoxicity in cancer patients
was investigated. In this triple-blind clinical trial 30 cancer patients
were randomly divided into the treatment group, receiving 40 mg
nano-curcumin capsules (15 patients) and the placebo group (15 patients)
twice a day for four chemotherapy courses. Kidney function was measured
at the beginning of the study and then at the end of each course of
chemotherapy. There was no significant difference in acute kidney injury
occurrence rate and creatinine and blood urine nitrogen serum levels
between the treatment and placebo groups at the end of each chemotherapy
course. (P value>0.05) and was not effective in preventing
the cisplatin induced nephrotoxicity in cancer patients in comparison
with the placebo. Additional studies with different doses and durations
of administration are recommended.